SAB Biotherapeutics, Inc. (SABS)
SAB Biotherapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Miami Beach, FL, US. The stock last traded at $3.82, up 1.50% on the session, giving a market capitalisation of $347.2M. On trailing twelve-month figures it carries a trailing P/E of 3.08, a net margin of 0.0%. Its beta of 0.53 implies it has historically moved less than the broad market.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
SAB Biotherapeutics, Inc. is most often compared with the following Healthcare names: